These data are consistent with multiple previous studies [15, 16, 19–21], which have shown that SETBP1 mutations occur in 4–7% CMML patients and are indicative of decreased OS and AML-free survival [22]. This evidence concerns the gene SETBP1 and acute myeloid leukemia.